Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response set includes several claims that match the label (notably indications and that follow-up clinician-directed procedures/manipulation occur), but multiple eligibility/clinical-reasoning claims are marked as not supported because the provided label excerpts do not contain that wording. Additionally, the audit is incomplete for sections that could affect safety accuracy (e.g., boxed warnings, pregnancy/lactation, pediatric use).
Category Scores
Accurate Statements
Xiaflex is indicated for adult patients with Dupuytren’s contracture with a palpable cord.
1 INDICATIONS AND USAGE
Xiaflex is indicated for adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
1 INDICATIONS AND USAGE
Xiaflex regimens include clinician-directed manipulation/follow-up procedures after injection (e.g., finger extension for Dupuytren’s; penile modeling for Peyronie’s).
2.1 Dosage and Administration for Dupuytren’s Contracture; 2.2 Dosage and Administration for Peyronie’s Disease
Unsupported Statements
Clinicians evaluate factors such as hand function and the pattern of finger involvement when considering Xiaflex for Dupuytren’s contracture.
Not supported by the supplied label excerpts provided for evaluation (no explicit hand-function/pattern criteria).
For Peyronie’s disease, the course and timing of disease must fit clinician judgment about where Xiaflex is most likely to be helpful.
No explicit label support in the provided excerpts for this timing/judgment criterion.
For Peyronie’s disease, eligibility depends on the patient’s overall risk profile.
No explicit label support in the provided excerpts.
Patient selection can hinge on risks associated with collagenase injection into connective tissue across both indications.
Label discusses risks and precautions, but the provided excerpts do not explicitly frame patient selection as hinging on injection risks in this broad/general way across both indications.
Patient selection can be influenced by prior reactions or complications from injection-based treatments.
The provided contraindications excerpt specifies hypersensitivity; it does not explicitly state that prior injection reactions/complications are a selection factor.
Clinicians screen carefully rather than treating broad groups of patients with nonspecific symptoms because Xiaflex is a biologically active enzyme used at specific tissue targets.
The provided excerpts do not explicitly support the stated rationale for screening behavior or the 'biologically active enzyme' explanation.
Contradictions
Important Omissions
Boxed warning evaluation (if present) and confirmation whether any claims conflict with boxed-warning content.
Importance:
Moderate
Comprehensive contraindication review using all contraindication text provided in section 4 (beyond partial confirmation by excerpt) to ensure no eligibility/selection claims indirectly conflict.
Importance:
Moderate
Pregnancy/lactation and pediatric-use sections were not included in the excerpt set for this audit.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are framed as selection/eligibility reasoning without explicit label support (e.g., clinician judgment/timing, risk profile, screening rationale). While they are not direct dosing/safety instructions, unsupported eligibility framing could mislead about appropriate candidate criteria.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims present explicit eligibility/selection and clinician-evaluation rationales that are not supported by the provided label excerpts; audit is also incomplete for certain label sections (e.g., boxed warnings/pregnancy/lactation/pediatrics).
Suggested Improvement
Limit claims to label-verbatim criteria and explicitly documented instructions (e.g., palpable cord; Peyronie’s plaque and curvature threshold; dosing course and required procedures). Remove or rephrase 'eligibility depends on' and broad 'screen carefully because...' rationales unless the full FDA label excerpts provide explicit support. Ensure the audit includes all relevant sections (4, 5, 6/7 as applicable, and 8/boxed warning sections if present).